00:00Novo Nordisk will cut the direct-to-consumer prices of Wegovi and Ozempic, bringing monthly costs for many cash-paying patients down to $349 and offering new introductory prices of $199 for the lowest doses.
00:13The shift follows a recent agreement between the company and the Trump administration aimed at expanding access, reducing government spending, and launching discounted GLP-1 options on the upcoming TrumpRx platform.
00:26Novo Nordisk says the new pricing is part of a broader effort to widen access through partnerships with telehealth providers, major retailers, and the federal government.
00:36Competing drugmaker Eli Lilly also reduced prices on its platform, intensifying the race to make weight loss and diabetes drugs more affordable.
Be the first to comment